Table 1.
Characteristics of the included studies.
| Author, year | Cases (SC/control) | Mode of POF induction | Type of Animal | Type of MSCs (source) | Cell dose/control | Route of transplantation | Follow-up | Outcomes |
|---|---|---|---|---|---|---|---|---|
| Yan PY, 2022 (15) | 10/10 | Chemotherapy-Induced | SD rat | ADMSCs (rat) | 5×105/0.9% saline | IV | 28 days | LH, FSH, E2 |
| Zhao SY, 2022 (34) | 14/14 | Chemotherapy-Induced | ICR mice | UCMSCs (human) | 2×106/0.9% saline | IV | 14 days | FSH, E2, AMH, PrF, PF, SF, AF |
| Wu Y, 2021 (16) | 9/6 | Autoimmune-Induced | SD rat | UCMSCs (human) | 2×106/0.9% saline | IO | 21 days | PrF, PF, SF, MF, CL |
| Deng TR, 2021 (11) | 8/8 | Chemotherapy-Induced | C57BL/6 mice | UCMSCs (human) | 1×106/PBS | IV | 28 days | FSH, E2, EC, PF, SF, AF |
| El-Derany MO, 2021 (10) | 30/30 | Radiation-Induced | SD rat | BMMSCs (rat) | 2×106/PBS | IV | 21 days | FSH, E2, EC |
| Zhang L, 2021 (44) | 5/5 | Chemotherapy-Induced | rabbit | UCMSCs (human) | 3×107/0.9% saline | IV | 28 days | FSH, FSH/LH, E2, INHB, AMH, GF, AF, CL |
| Zhang XY, 2021 (8) | 20/20 | Autoimmune-Induced | SD rat | UCMSCs (human) | 1×106/PBS | IO | 20 days | LH, FSH, E2, EC, NF |
| Li Q, 2020 (17) | 12/12 | Chemotherapy-Induced | SD rat | BMMSCs (rat) | 1×106/0.9% saline | IV | 45 days | FSH, E2, PrF, GF, MF, AF |
| Wang Z, 2020 (9) | 15/15 | Autoimmune-Induced | SD rat | UCMSCs (human) | 4×106/PBS | IV | 21 days | PrF, PF, SF, MF, CL |
| Xu YY, 2020 (35) | 16/16 | Chemotherapy-Induced | C57BL/6 mice | MenSCs (human) | 4×106/PBS | IV | 14 days | E2 |
| Zhang J, 2020 (45) | 5/5 | Chemotherapy-Induced | rabbit | UCMSCs (human) | 3×107/0.9% saline | IV | 28 days | FSH, E2 |
| Hou QN, 2019 (20) | 15/15 | Chemotherapy-Induced | SD rat | PMSCs (human) | 2×107/0.9% saline | IV | 15 days | PF, SF, MF, AF |
| Lin HW, 2019 (36) | 12/12 | Chemotherapy-Induced | BALB/c mice | UCMSCs (human) | 4×105/0.9% saline | IV | 7 days | LH, FSH, E2, |
| Manshadi MD, 2019 (12) | 6/6 | Chemotherapy-Induced | Wistar rat | MenSCs (human) | 1×106/PBS | IV | 28 days | E2 |
| Tan L, 2019 (19) | 10/10 | Chemotherapy-Induced | SD rat | UCMSCs (human) | 1×106/0.9% saline | IV | 17 days | LH, FSH, E2, GF, AF, CL |
| Yang YJ, 2019 (37) | 15/15 | Chemotherapy-Induced | C57BL/6 mice | UCMSCs (human) | 2×105/PBS | IO | 28 days | FSH, E2, AMH, PrF, PF, SF, AnF, EC |
| Zheng Q, 2019 (18) | 12/12 | Chemotherapy-Induced | SD rat | UCMSCs (human) | 5×106/PBS | IV | 14 days | EC, PrF, PF, SF, EA |
| Zhao Y, 2019 (38) | 15/15 | Chemotherapy-Induced | CD-1 mice | UCMSCs (human) | 2×106/0.9% saline | IV | 21 days | FSH, E2, AMH, PrF, GF, AF |
| Zhuang YQ, 2019 (39) | 12/12 | Chemotherapy-Induced | ICR mice | UCMSCs (human) | 1×106/sterilizing water | IV | 14 days | FSH/LH, AMH, PF, SF, PrF, AnF |
| Li J, 2018 (13) | 25/25 | Chemotherapy-Induced | C57BL/6 mice | CPMSCs (human) | 8×106/0.9% saline | IV | 28 days | FSH, E2, EC |
| Li XR, 2018 (23) | 20/20 | Chemotherapy-Induced | Wistar rat | BMMSCs (rat) | 2×106/PBS | IO | 30 days | FSH, E2 |
| Wang LL, 2018 (22) | 25/25 | Chemotherapy-Induced | Wistar rat | BMMSCs (rat) | 1×106/PBS | IO | 30 days | FSH, E2, NF, PF, SF, AnF, PrF |
| Yin N, 2018 (40) | 17/18 | Autoimmune-Induced | BALB/c mice | PMSCs (human) | 1×106/PBS | IV | 14 days | FSH, E2, PF, SF |
| Zhang LL, 2018 (21) | 22/22 | Chemotherapy-Induced | SD rat | UCMSCs (human) | 1×106/sterilizing water | IV | 17 days | FSH/LH, AMH, INHB, GF, AF, CL |
| Badawy A, 2017 (41) | 10/10 | Chemotherapy-Induced | BALB/c mice | BMMSCs (mice) | 5×105/0.9% saline | IV | 21 days | FSH, E2 |
| Jia XC, 2017 (25) | 24/24 | Chemotherapy-Induced | SD rat | UCMSCs (human) | 6×106/0.9% saline | IV | 32 days | E2, PF, MF |
| Wu Q, 2017 (24) | 12/12 | Chemotherapy-Induced | SD rat | BMMSCs (rat) | 3×106/0.9% saline | IV | 28 days | FSH, E2, LH |
| Elfayomy AK, 2016 (29) | 12/15 | Chemotherapy-Induced | Wistar rat | UCMSCs (human) | 2×106/0.9% saline | IO | 28 days | FSH, E2, AnF |
| Gabr H, 2016 (28) | 12/12 | Chemotherapy-Induced | Albino rat | BMMSCs (rat) | 1×106/0.9% saline | IV | 14 days | FSH, E2, |
| Song D, 2016 (27) | 7/7 | Chemotherapy-Induced | Wistar rat | UCMSCs (human) | 1×105/0.9% saline | IO | 28 days | FSH, E2, AMH, EF, PF, SF, PrF |
| Su J, 2016 (26) | 16/14 | Chemotherapy-Induced | SD rat | ADMSCs (rat) | 2×106/PBS | IO | 28 days | E2, AnF |
| Qin JJ, 2015 (31) | 12/12 | Chemotherapy-Induced | SD rat | BMMSCs (rat) | 3×106/0.9% saline | IV | 28 days | FSH, E2, |
| Ye XF, 2015 (30) | 22/22 | Chemotherapy-Induced | Wistar rat | BMMSCs (rat) | 1×107/0.9% saline | IO | 30 days | FSH, E2, NF, |
| Fu XF, 2013 (42) | 20/20 | Autoimmune-Induced | BALB/c mice | UCMSCs (human) | 2×106/0.9% saline | IO | 30 days | FSH, E2, SF, PF, AnF, PrF |
| Li J, 2012 (32) | 8/8 | Chemotherapy-Induced | SD rat | AFMSCs (human) | 2×106/0.9% saline | IV | 7 days | FSH, E2 |
| Wang Y, 2011 (43) | 15/15 | Chemotherapy-Induced | C57 mice | BMMSCs (mice) | 2×105/PBS | IO | 28 days | FSH, LH, |
| Fu X, 2008 (33) | 20/20 | Chemotherapy-Induced | Wistar rat | BMMSCs (rat) | 2×106/0.9% saline | IO | 28 days | FSH, E2 |
UC-MSCs, umbilical cord mesenchymal stem cells; BMMSCs, bone marrow mesenchymal stem cells; MenSCs, Menstrual blood mesenchymal stem cells; PMSCs, placenta mesenchymal stem cells; CPMSCs, chorionic plate mesenchymal stem cells; ADMSCs, adipose mesenchymal stem cell; AFMSCs, amniotic fluid mesenchymal stem cells; IV, intravenously injected; IO, intra ovary injected; POF, premature ovarian failure; SD rat, Sprague-Dawley rat; pZP3, zona pellucida glycoprotein 3; PBS, phosphate-buffered saline; LH, luteinizing hormone; FSH, follicle-stimulating hormone; E2, estradiol; AMH, anti Mullerian hormone; INHB, inhibin B; EC, estrus cycle; NF, number of follicles; GF, growing follicle; AF, atretic follicles; CL, corpora luteum; AnF, antral follicles; PrF, primordial follicles; PF, primary follicles; SF, secondary follicles; MF, mature follicles; EF, early antral.